{"nct_id":"NCT03829410","title":"Onvansertib in Combination With FOLFIRI and Bevacizumab for Second Line Treatment of Metastatic Colorectal Cancer Patients With a KRAS Mutation","status":"COMPLETED","status_verified_date":"2025-02","start_date":"2019-06-24","start_date_type":"ACTUAL","primary_completion_date":"2024-01-29","primary_completion_date_type":"ACTUAL","completion_date":"2024-01-29","completion_date_type":"ACTUAL","phases":["PHASE1","PHASE2"],"tickers":["CRDF"]}